<DOC>
	<DOCNO>NCT02864290</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability AGS62P1 give two dose schedule ( Schedule A , every three week [ Q3W ] Schedule B , weekly ) , subject acute myeloid leukemia ( AML ) determine maximum tolerate dose ( MTD ) . In addition , study ass pharmacokinetics ( PK ) , immunogenicity anti-leukemic activity AGS62P1 .</brief_summary>
	<brief_title>A Study Evaluate Escalating Doses AGS62P1 Given Monotherapy Subjects With Acute Myeloid Leukemia ( AML )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>Subject morphologically document primary secondary AML World Health Organization ( WHO ) criterion ( 2008 ) relapse refractory fail least 1 regimen candidate establish salvage treatment regimens Subject Eastern Cooperative Oncology Group performance score ( ECOG ) ≤ 2 Subject adequate renal function estimate creatinine clearance ≥ 30 mL/min CockcroftGault equation adjust body weight Subject total bilirubin ≤ 1.5 x upper limit normal ( ULN ) , albumin ≥ 2.5 g/d , aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤ 2.5 x upper limit normal ( ULN ) Negative pregnancy test woman child bear potential Sexually active fertile subject , partner , must agree use medically accept doublebarrier method contraception ( e.g. , barrier method , include male condom , female condom , diaphragm spermicidal gel ) study least 6 week termination study therapy Subjects must competent comprehend , provide write informed consent , date independent ethic committee/institutional review board/research ethic board ( IEC/IRB/REB ) approve informed consent form Subject diagnosis acute promyelocytic leukemia ( APL ) Subject preexist sensory motor neuropathy Grade ≥ 2 baseline Subject receive small molecule therapy , radiotherapy , immunotherapy , monoclonal antibody , investigational drug , chemotherapy within 14 day first dose study drug , exception hydroxyurea Subject Grade ≥ 2 persistent nonhematological toxicity relate allotransplant Subject Graft v . Host Disease ( GVHD ) receive treatment systemic glucocorticoid &gt; 10 mg/day equivalent prednisone ; however , treatment low dose glucocorticoid ( ≤ 10 mg/day equivalent prednisone ) permit The use systemic glucocorticoid excess 10 mg/day equivalent prednisone permit provided treatment GVHD ( e.g . chronic obstructive pulmonary disease , antiemetic , infusion reaction ) . The chronic use topical , inhaled , locally injected steroid permit Subject require concomitant use Pgp inhibitor ( ) inducer ( ) exclude . Subject discontinues use Pgp modulators must washout period least 14 day prior first dose AGS62P1 Subject know current central nervous system ( CNS ) disease Active angina Class III IV Congestive Heart Failure ( New York Heart Association CHF Functional Classification System ) clinically significant cardiac disease within 12 month first dose study drug , include myocardial infarction , unstable angina , Grade 2 great peripheral vascular disease , congestive heart failure , uncontrolled hypertension , arrhythmias control medication Subject clinical evidence Disseminated Intravascular Coagulation Subject know positivity human immunodeficiency virus Subject know positivity Hepatitis B surface antigen Hepatitis C antibody Subject uncontrolled active infection require treatment fever 38.3°C high 48 hour first dose study drug . Controlled infection ( i.e . 3 negative culture complete antibiotic and/or stable fungal infection therapy ) allow provide subject temperature &lt; 38.3°C within 48 hour first dose study drug . Subject know sensitivity component investigational product AGS62P1 : AGS62P1 LHistidine base LHistidine HCl α , α Trehalose Dihydrate Polysorbate 20 Major surgery within 28 day first dose study drug Subject pregnant lactating Subject condition situation may put subject significant risk , may confound study result , may interfere significantly subject 's participation study Subject medical , psychiatric , addictive disorder compromise ability subject give write informed consent and/or comply procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Pharmacokinetics AGS62P1</keyword>
	<keyword>AGS62P1</keyword>
	<keyword>AML</keyword>
	<keyword>Acute Myeloid Leukemia</keyword>
</DOC>